Adriamycin causes hyperlipemia as a consequence of nephrotoxicity.
@article{Bizzi1983AdriamycinCH, title={Adriamycin causes hyperlipemia as a consequence of nephrotoxicity.}, author={Alberto Bizzi and Luca Ceriani and M Gerundino and Annamaria Spina and Maria Teresa Tacconi and E. Veneroni}, journal={Toxicology letters}, year={1983}, volume={18 3}, pages={ 291-300 } }
Adriamycin induced hyperlipemia: its features and mechanism(s) in rats were investigated. Massive hyperlipemia occurred 14-21 days after a single dose of adriamycin (7.5 mg/kg i.v.). All lipoprotein fractions were affected. Mild but significant changes in tissues were observed (liver and intestine triglycerides and kidney phospholipids were reduced). Lipid synthesis and secretion was decreased, as shown by the Triton WR1339 test 7 days after treatment, but subsequently returned to normal… CONTINUE READING
Topics from this paper.
Citations
Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS
Distribution of anticancer antibiotic daunomycin in the rat heart and kidney revealed by immunocytochemistry using monoclonal antibodies
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED
Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats
VIEW 2 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED
Improved distribution and reduced toxicity of adriamycin bound to albumin-heparin microspheres
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED
Does Adriamycine, Cytoxan with Taxol Treatment Affect FBS and Lipid Profile in Breast Cancer Patients
VIEW 1 EXCERPT
CITES BACKGROUND